SG10201805231WA - 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof - Google Patents

2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

Info

Publication number
SG10201805231WA
SG10201805231WA SG10201805231WA SG10201805231WA SG10201805231WA SG 10201805231W A SG10201805231W A SG 10201805231WA SG 10201805231W A SG10201805231W A SG 10201805231WA SG 10201805231W A SG10201805231W A SG 10201805231WA SG 10201805231W A SG10201805231W A SG 10201805231WA
Authority
SG
Singapore
Prior art keywords
methods
polymorphic forms
bardoxolone methyl
difluoropropionamide
derivatives
Prior art date
Application number
SG10201805231WA
Inventor
Ahmad Y Sheikh
Alessandra Mattei
Xiu C Wang
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG10201805231WA publication Critical patent/SG10201805231WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF ABS TRACT 5 The present invention relates generally to the compound: N-((4aS,6aR,6138,8aR,12a8,14aR,14bS)-11- cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3 ,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,1 4a,14b- octadecahydropicen-4a-y1)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof 10 FIG. 1 116
SG10201805231WA 2013-04-24 2014-04-24 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof SG10201805231WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361815502P 2013-04-24 2013-04-24

Publications (1)

Publication Number Publication Date
SG10201805231WA true SG10201805231WA (en) 2018-08-30

Family

ID=50842351

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201508752WA SG11201508752WA (en) 2013-04-24 2014-04-24 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
SG10201805231WA SG10201805231WA (en) 2013-04-24 2014-04-24 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201508752WA SG11201508752WA (en) 2013-04-24 2014-04-24 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

Country Status (36)

Country Link
US (4) US9856286B2 (en)
EP (2) EP3453715A1 (en)
JP (2) JP6409050B2 (en)
KR (2) KR20150144807A (en)
CN (1) CN105324389B (en)
AR (1) AR096046A1 (en)
AU (2) AU2014257072C1 (en)
BR (1) BR112015027012B1 (en)
CA (1) CA2909066C (en)
CL (1) CL2015003135A1 (en)
CR (1) CR20150620A (en)
CY (1) CY1120570T1 (en)
DK (1) DK2989114T3 (en)
DO (1) DOP2015000263A (en)
EC (1) ECSP23088864A (en)
ES (1) ES2683626T3 (en)
HK (2) HK1221470A1 (en)
HR (1) HRP20181321T1 (en)
HU (1) HUE039899T2 (en)
IL (1) IL242183B (en)
LT (1) LT2989114T (en)
MX (1) MX2015014792A (en)
MY (1) MY182677A (en)
PE (1) PE20160006A1 (en)
PH (1) PH12015502459B1 (en)
PL (1) PL2989114T3 (en)
PT (1) PT2989114T (en)
RS (1) RS57571B1 (en)
RU (2) RU2693833C2 (en)
SG (2) SG11201508752WA (en)
SI (1) SI2989114T1 (en)
TW (2) TW201936625A (en)
UA (1) UA118348C2 (en)
UY (2) UY35534A (en)
WO (1) WO2014176415A1 (en)
ZA (1) ZA201507481B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58486B1 (en) 2008-01-11 2019-04-30 Reata Pharmaceuticals Inc Synthetic triterpenoids and methods of use in the treatment of disease
JP5529851B2 (en) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド Antioxidative inflammation modulator: oleanolic acid derivative with amino modification and other modifications in C-17
MX2010011435A (en) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Compounds including an anti-inflammatory pharmacore and methods of use.
SI2841445T1 (en) 2012-04-27 2017-12-29 Reata Pharmaceuticals, Inc. 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
PT2892912T (en) 2012-09-10 2019-07-12 Reata Pharmaceuticals Inc C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
TW201936625A (en) 2013-04-24 2019-09-16 美商艾伯維有限公司 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
CN106309451A (en) * 2016-08-14 2017-01-11 吴芊葭 Pharmaceutical composition of cefuroxime axetil and medical application of pharmaceutical composition
CN106279344A (en) * 2016-08-14 2017-01-04 吴芊葭 A kind of native compound separated from Radix Saposhnikoviae and preparation method thereof, medical applications
MX2019005401A (en) 2016-11-08 2019-08-05 Reata Pharmaceuticals Inc Methods of treating alport syndrome using bardoxolone methyl or analogs thereof.
CN108558985B (en) * 2018-05-19 2019-06-07 河南省科学院高新技术研究中心 Betulic acid derivative and its synthetic method and application
KR20210044833A (en) * 2018-08-15 2021-04-23 아이비바 바이오파마, 인크. Multiple Kinase Inhibitors of VEGF and TGF Beta and Uses thereof
MX2021002060A (en) 2018-08-20 2021-07-21 Janssen Pharmaceutica Nv Inhibitors of keap1-nrf2 protein-protein interaction.
WO2020190733A1 (en) * 2019-03-15 2020-09-24 University Of Rhode Island Board Of Trustees pHLIP®-MEDIATED TARGETING OF CORTICOSTEROIDS TO DISEASED TISSUE
WO2020226201A1 (en) * 2019-05-08 2020-11-12 경상대학교병원 Pharmaceutical composition for preventing or treating skin hypochromatism, health functional food, and cosmetic composition
EP4077347A1 (en) * 2019-12-19 2022-10-26 Reata Pharmaceuticals, Inc. Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof
CN117015548A (en) * 2021-01-18 2023-11-07 里亚塔医药公司 Synthetic ursolic acid derivatives and methods of use thereof
CN113197905B (en) * 2021-04-23 2022-04-19 浙江大学 Application of triterpenoid in preparation of medicine for treating neuroblastoma
CN114344308A (en) * 2021-12-22 2022-04-15 山西医科大学第二医院 Application of bardoxolone methyl in preparation of medicine for preventing and treating osteoarthritis
EP4349847A1 (en) * 2022-09-21 2024-04-10 Sicor Società Italiana Corticosteroidi S.r.l. Process and intermediates for preparation of omaveloxolone and salts thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
US6689767B2 (en) 2000-09-29 2004-02-10 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
JP2004509972A (en) 2000-09-29 2004-04-02 リージェンツ　オブ　ザ　ユニバーシティ　オブ　ミネソタ Triterpenes with fungicidal activity against yeast
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
EP1395255A4 (en) 2000-11-28 2007-09-12 Univ Texas Cddo-compounds and combination therapies thereof
EP1465615B1 (en) 2002-01-15 2012-08-01 Trustees of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
EP1465914B1 (en) 2002-01-18 2008-12-17 Regents Of The University Of Minnesota Triterpene quaternary salts as biologically active surfactants
AU2003303128A1 (en) 2002-05-13 2004-08-13 Trustees Of Dartmouth College Inhibitors and methods of use thereof
WO2005042002A2 (en) 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
CA2614110A1 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
WO2007112043A2 (en) 2006-03-23 2007-10-04 Advanced Life Sciences Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
US20070249561A1 (en) 2006-04-25 2007-10-25 Taylor Bradley K Pharmacological method for treatment of neuropathic pain
WO2008016095A1 (en) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US7714012B2 (en) 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
JP2008247898A (en) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd Agent for preventing or treating oxidative-stress-associated eye disease, containing triterpenoid as active ingredient
US20080254055A1 (en) 2007-04-11 2008-10-16 John Erich Oblong Compositions for Regulation of Hair Growth
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
US20090048205A1 (en) 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
RS58486B1 (en) 2008-01-11 2019-04-30 Reata Pharmaceuticals Inc Synthetic triterpenoids and methods of use in the treatment of disease
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
JP5529851B2 (en) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド Antioxidative inflammation modulator: oleanolic acid derivative with amino modification and other modifications in C-17
MX2010011435A (en) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Compounds including an anti-inflammatory pharmacore and methods of use.
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
RS55631B1 (en) 2008-04-18 2017-06-30 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
CA2731650A1 (en) 2008-07-22 2010-01-28 Tadashi Honda Monocyclic cyanoenones and methods of use thereof
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
MY173715A (en) 2009-02-13 2020-02-18 Reata Pharmaceuticals Inc Delayed release, oral dosage compositions that contain amorphous cddo-me
WO2010127029A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
JP5990160B2 (en) * 2010-04-12 2016-09-07 リアタ ファーマシューティカルズ インコーポレイテッド Methods of treating obesity using antioxidant inflammation modulators
US20130288985A1 (en) 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
US8513436B2 (en) 2010-12-17 2013-08-20 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
EP2683731B1 (en) 2011-03-11 2019-04-24 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
WO2012154554A1 (en) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
SI2841445T1 (en) * 2012-04-27 2017-12-29 Reata Pharmaceuticals, Inc. 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013169740A2 (en) 2012-05-08 2013-11-14 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
PT2892912T (en) 2012-09-10 2019-07-12 Reata Pharmaceuticals Inc C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
JP2015527407A (en) 2012-09-10 2015-09-17 アッヴィ・インコーポレイテッド Glycyrrhetinic acid derivatives and methods of use thereof
SG11201501800UA (en) 2012-09-10 2015-04-29 Reata Pharmaceuticals Inc C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
TW201936625A (en) 2013-04-24 2019-09-16 美商艾伯維有限公司 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
IL285832B2 (en) 2013-08-23 2024-01-01 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
CN107074801B (en) 2014-01-24 2021-11-05 里亚塔医药公司 Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclenones as antioxidant inflammatory modulators
AU2016219109B2 (en) 2015-02-12 2020-05-14 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant iflammation modulators
AU2016326704B2 (en) 2015-09-23 2021-01-28 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses
MX2019005401A (en) 2016-11-08 2019-08-05 Reata Pharmaceuticals Inc Methods of treating alport syndrome using bardoxolone methyl or analogs thereof.

Also Published As

Publication number Publication date
DOP2015000263A (en) 2015-12-15
RU2019120236A (en) 2019-07-22
CN105324389A (en) 2016-02-10
PL2989114T3 (en) 2018-10-31
EP2989114A1 (en) 2016-03-02
RU2693833C2 (en) 2019-07-05
UA118348C2 (en) 2019-01-10
SI2989114T1 (en) 2018-09-28
MX2015014792A (en) 2016-03-07
UY39092A (en) 2021-03-26
ZA201507481B (en) 2021-05-26
TW201936625A (en) 2019-09-16
NZ749873A (en) 2020-09-25
AR096046A1 (en) 2015-12-02
US20180094020A1 (en) 2018-04-05
CY1120570T1 (en) 2019-07-10
SG11201508752WA (en) 2015-11-27
DK2989114T3 (en) 2018-08-20
WO2014176415A1 (en) 2014-10-30
CA2909066C (en) 2021-08-03
UY35534A (en) 2014-10-31
PH12015502459A1 (en) 2016-02-22
HUE039899T2 (en) 2019-02-28
PE20160006A1 (en) 2016-02-03
KR20210018555A (en) 2021-02-17
US20140323579A1 (en) 2014-10-30
HRP20181321T1 (en) 2018-10-19
JP2019023200A (en) 2019-02-14
CN105324389B (en) 2018-02-06
RU2015150069A3 (en) 2018-03-21
CR20150620A (en) 2016-01-12
MY182677A (en) 2021-01-29
AU2014257072C1 (en) 2020-07-16
AU2019200341A1 (en) 2019-02-07
TW201518314A (en) 2015-05-16
BR112015027012B1 (en) 2023-01-10
ECSP23088864A (en) 2023-12-29
KR20150144807A (en) 2015-12-28
BR112015027012A2 (en) 2017-07-25
IL242183B (en) 2019-10-31
JP6409050B2 (en) 2018-10-17
EP3453715A1 (en) 2019-03-13
EP2989114B1 (en) 2018-05-23
HK1222179A1 (en) 2017-06-23
US11117927B2 (en) 2021-09-14
TWI649330B (en) 2019-02-01
ES2683626T3 (en) 2018-09-27
RU2019120236A3 (en) 2019-12-04
PT2989114T (en) 2018-10-10
AU2014257072A1 (en) 2015-10-29
JP2016517869A (en) 2016-06-20
US20200062800A1 (en) 2020-02-27
AU2014257072B2 (en) 2018-10-18
US9856286B2 (en) 2018-01-02
LT2989114T (en) 2018-08-10
HK1221470A1 (en) 2017-06-02
CL2015003135A1 (en) 2016-06-10
PH12015502459B1 (en) 2016-02-22
RU2015150069A (en) 2017-05-29
CA2909066A1 (en) 2014-10-30
RS57571B1 (en) 2018-11-30
US20220073559A1 (en) 2022-03-10
KR102342915B1 (en) 2021-12-24
US11873320B2 (en) 2024-01-16

Similar Documents

Publication Publication Date Title
SG10201805231WA (en) 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
MX357060B (en) 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof.
SV2017005487A (en) DERIVATIVES OF 4H-PIRROL [3,2-C] PIRIDIN-4-ONA
PH12015502248A1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
NZ711192A (en) Process for making benzoxazepin compounds
MD20160105A2 (en) 2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
MX2015013224A (en) Macrocyclic and bicyclic inhibitors of hepatitis c virus.
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
MX371011B (en) Intermediates and methods for synthesizing calicheamicin derivatives.
BR112015030589A2 (en) polymorphic forms of icotinib phosphate and their uses
BR112015030591A2 (en) icotinib maleate polymorph forms and uses thereof
IN2013CH05689A (en)
WO2014153113A3 (en) Processes and intermediates for the preparation of 3 amino-n-cyclopropyl-2 hydroxypropionamide derivatives
MX2016005222A (en) Acid dyes, process for the production thereof and their use.
LV15016A (en) Polymorphyc forms of n-carbamoyl-4(r)-phenyl-2-pyrrolidinone